Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 24 , ISSUE 7 ( July, 2020 ) > List of Articles

REVIEW ARTICLE

Past, Present, and Future of Remdesivir: An Overview of the Antiviral in Recent Times

Shouvik Choudhury, Dwaipayan S Chakraborty, Sandeep Lahiry, Suparna Chatterjee

Keywords : Clinical trials, COVID-19 drug treatment, Viral genome

Citation Information : Choudhury S, Chakraborty DS, Lahiry S, Chatterjee S. Past, Present, and Future of Remdesivir: An Overview of the Antiviral in Recent Times. Indian J Crit Care Med 2020; 24 (7):570-574.

DOI: 10.5005/jp-journals-10071-23491

License: CC BY-NC 4.0

Published Online: 05-09-2020

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

In the current COVID-19 pandemic, evidence to justify the use of any specific antiviral drug with proven efficacy is not yet available. Antiviral drug development always remains a challenge to the scientists. Remdesivir has emerged as a promising molecule, based on results of clinical trials and observational studies and has receieved marketing approval for COVID-19 treatment under “emergency use authorization” in countries such as United States. Remdesivir is a newer antiviral drug that acts as an RNA-dependent RNA polymerase (RdRp) inhibitor targeting the viral genome replication process. Therapeutic efficacy was first demonstrated by suppressing viral replication in Ebola-infected rhesus monkeys. It is available for parenteral use with reasonable safety and tolerability profile. Multiple clinical trials are going on in many countries to evaluate its safety, efficacy and tolerability. Positive outcome will make the drug capable of meeting the demand generated by both the current pandemic and future outbreak.


PDF Share
  1. Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 2019;10(1):2342. DOI: 10.1038/s41467-019-10280-3.
  2. Gordon CJ, Tchesnokov EP, Feng JY, et al. The antiviral compound remdesivir potently inhibits RNA dependent RNA polymerase from middle east respiratory syndrome coronavirus. J Biol Chem 2020;295(15):4773–4779. DOI: 10.1074/jbc.AC120.013056.
  3. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C. Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more. Arch Med Res 2020. S0188-4409(20):30699-8 10.1016/j.arcmed.2020.05.001.
  4. “Summary on Compassionate Use: Remdesivir Gilead” (https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf) (PDF). European Medicines Agency. Retrieved 1 May 2020.
  5. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016;531(7594):381–385. DOI: 10.1038/nature17180.
  6. Summaries of evidence from selected experimental therapeutics. 2018 as of October https://www.who.int/ebola/drc-2018/summaries-of-evidenceexperimental-therapeutics.pdf?ua=1.
  7. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020(12). DOI: 10.1073/pnas.1922083117.
  8. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11(1):222. DOI: 10.1038/s41467-019-13940-6.
  9. Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg 2019;21(4):271–281. DOI: 10.1177/1098612X19825701.
  10. Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med 2019;11(494). DOI: 10.1126/scitranslmed.aau9242pii: eaau9242.
  11. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269–271. DOI: 10.1038/s41422-020-0282-0.
  12. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395(10236):1569–1578. DOI: 10.1016/S0140-6736(20)31022-9.
  13. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med 2020. DOI: 10.1056/NEJMoa2015301.
  14. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med 2020;382(24):2327–2336. DOI: 10.1056/NEJMoa2007016.
  15. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 - preliminary report. N Engl J Med 2020. DOI: 10.1056/NEJMoa2007764NEJMoa2007764.
  16. US Food & Drug Administration (FDA), Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. FDA News Release. 1st May 2020. (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment).
  17. Gilead Announces Results from Phase 3 Trial of Investigational Antiviral Remdesivir in Patients with Severe COVID-19 [news release]. Foster City, CA; April 29, 2020: Gilead Sciences.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.